BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36809234)

  • 21. Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
    Yang M; Zhang J; Wei D; Yu T; Chen Z; Liu X; Zhu H
    BMC Cancer; 2024 Feb; 24(1):196. PubMed ID: 38347460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?
    Dogan M; Algin E; Guven ZT; Baykara M; Kos TF; Bal O; Zengin N
    Curr Med Res Opin; 2018 May; 34(5):857-863. PubMed ID: 29161926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
    Prelaj A; Rebuzzi SE; Pizzutilo P; Bilancia M; Montrone M; Pesola F; Longo V; Del Bene G; Lapadula V; Cassano F; Petrillo P; Bafunno D; Varesano N; Lamorgese V; Mastrandrea A; Ricci D; Catino A; Galetta D
    Clin Lung Cancer; 2020 Jul; 21(4):365-377.e5. PubMed ID: 32245624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased platelet-to-lymphocytes ratio is associated with poor long-term prognosis in patients with pancreatic cancer after surgery.
    Yu J; Ding Z; Yang Y; Liu S
    Medicine (Baltimore); 2018 Jun; 97(25):e11002. PubMed ID: 29923983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation and clinical usefulness of pre- and postoperative systemic inflammatory parameters as prognostic markers in patients with potentially resectable pancreatic cancer.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Ogata Y
    Pancreatology; 2020 Mar; 20(2):239-246. PubMed ID: 31862230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.
    Gou M; Qu T; Wang Z; Yan H; Si Y; Zhang Y; Dai G
    J Immunol Res; 2021; 2021():2549295. PubMed ID: 34993252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer.
    Hu C; Bai Y; Li J; Zhang G; Yang L; Bi C; Zhao B; Yang Y; Li R; Wu H; Wang Q; Qin Y
    BMC Urol; 2020 May; 20(1):57. PubMed ID: 32460817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
    Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
    Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
    Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
    Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
    Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
    Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors.
    Bai R; Li L; Chen X; Chen N; Song W; Zhang Y; Lv Z; Han F; Zhao Y; Li W; Cui J
    J Oncol; 2021; 2021():9935076. PubMed ID: 34335763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study.
    Zhang LX; Wei ZJ; Xu AM; Zang JH
    Int J Surg; 2018 Aug; 56():320-327. PubMed ID: 29969732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
    Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
    BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
    Guida M; Bartolomeo N; Quaresmini D; Quaglino P; Madonna G; Pigozzo J; Di Giacomo AM; Minisini AM; Tucci M; Spagnolo F; Occelli M; Ridolfi L; Queirolo P; De Risi I; Valente M; Sciacovelli AM; Chiarion Sileni V; Ascierto PA; Stigliano L; Strippoli S
    J Transl Med; 2022 Apr; 20(1):159. PubMed ID: 35382857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
    Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; El-Rayes BF; Master VA; Ramalingam SS; Owonikoko TK; Harvey RD
    Cancer; 2019 Jan; 125(1):127-134. PubMed ID: 30329148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.
    Jia W; Yuan L; Ni H; Xu B; Zhao P
    Technol Cancer Res Treat; 2021; 20():15330338211034291. PubMed ID: 34308689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.
    Zer A; Sung MR; Walia P; Khoja L; Maganti M; Labbe C; Shepherd FA; Bradbury PA; Feld R; Liu G; Iazzi M; Zawisza D; Nouriany N; Leighl NB
    Clin Lung Cancer; 2018 Sep; 19(5):426-434.e1. PubMed ID: 29803574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.